NeoVax + Nivolumab for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a custom-made vaccine for ovarian cancer, used with Nivolumab. It targets ovarian cancer patients who need new treatment options. The vaccine boosts the immune response using the patient's own cancer proteins, while Nivolumab keeps the immune system active.
Who Is on the Research Team?
Panagiotis Konstantinopoulos, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute
Are You a Good Fit for This Trial?
This trial is for women over 18 with certain types of ovarian cancer who are in good health and not pregnant. They must have a performance status indicating they can care for themselves, agree to use contraception, and be willing to follow the study's procedures. Those with non-epithelial tumors, serious illnesses besides cancer, or recent major surgery cannot join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 5 NeoVax immunizations over a 3-week period, with two booster vaccinations at Week 12, and Nivolumab administered by IV infusion every 2 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NeoVax
- Nivolumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Dana-Farber Cancer Institute
Lead Sponsor
United States Department of Defense
Collaborator